Research location
Media
Pennsylvania, United States
Advertisement
Research activity in Media
Pennsylvania, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 195 trials and 195 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Media
195 linked trials · page 1 of 4A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation
RECRUITING
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With DepressionNCT07610473 · 2026-05-14 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 in Patients With DepressionNCT07300969 · 2025-12-16 · 1 site observation
RECRUITING
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222 · 2025-09-17 · 1 site observation
RECRUITING
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 · 2025-03-03 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Study of ALTO-300 in MDDNCT05922878 · 2023-06-08 · 1 site observation
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25 · 1 site observation
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation
RECRUITING
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.NCT07222917 · 2025-12-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerNCT06732401 · 2025-08-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · 2025-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDNCT06979544 · 2025-06-16 · 1 site observation
COMPLETED
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014 · 2025-02-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Different Doses of BI 1569912 in People With DepressionNCT06558344 · 2024-10-01 · 1 site observation
COMPLETED
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)NCT05554354 · 2024-09-13 · 1 site observation
TERMINATED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantNCT06514742 · 2024-06-26 · 1 site observation
TERMINATED
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 · 2024-03-18 · 1 site observation
COMPLETED
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialNCT05554380 · 2023-09-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)NCT05879614 · 2023-09-01 · 1 site observation
WITHDRAWN
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT TrialNCT05710328 · 2023-05-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyNCT05568472 · 2023-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)NCT05518149 · 2022-09-22 · 1 site observation
TERMINATED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyNCT05455684 · 2022-06-22 · 1 site observation
COMPLETED
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyNCT05053152 · 2022-04-20 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061706 · 2021-09-30 · 1 site observation
COMPLETED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.